Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues
The transcriptional co-activator YES-associated protein (YAP) has been reported to act as both an oncogene and tumor suppressor in breast cancers. In this study, we evaluated YAP expression immunohistochemically in 324 breast cancer tissues and correlated the expression with clinicopathological find...
Gespeichert in:
| Veröffentlicht in: | Human pathology 2017-10, Vol.68, p.166-174 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 174 |
|---|---|
| container_issue | |
| container_start_page | 166 |
| container_title | Human pathology |
| container_volume | 68 |
| creator | Cao, Lanqing Sun, Ping-Li Yao, Min Jia, Meng Gao, Hongwen |
| description | The transcriptional co-activator YES-associated protein (YAP) has been reported to act as both an oncogene and tumor suppressor in breast cancers. In this study, we evaluated YAP expression immunohistochemically in 324 breast cancer tissues and correlated the expression with clinicopathological findings and patient survival data. Additionally, we reviewed the literature to clarify the role of YAP in breast cancer. We detected YAP, estrogen receptor, progesterone receptor (PR), and human epidermal growth receptor-2 (HER2) expression and a Ki67 labeling index >20% in 53.4%, 49.0%, 45.0%, 28.3%, and 57.4% of invasive ductal carcinoma tissues, respectively. YAP is mainly localized within the tumor cell nuclei, and its expression was associated with the PR status and luminal A subtype. YAP expression also inversely correlated with the HER2 and Ki67 levels and lymph node metastasis. Kaplan-Meier curves revealed associations of YAP expression with favorable disease-free survival (DFS) and overall survival in patients with luminal A breast cancer and with favorable DFS association among patients with invasive ductal carcinoma, luminal B (HER2−), and luminal B (HER2+) breast cancers. A multivariate Cox analysis revealed that YAP expression and PR status were independent favorable predictors of DFS and overall survival, respectively, among patients with breast cancer, whereas tumor-node-metastasis stage and an old age were independent predictors of a poor DFS. Our results, together with the literature review findings, suggest that YAP could be a prognostic marker in patients with breast cancer.
•YAP protein is directly associated with PR status and luminal A subtype.•YAP protein is inversely associated with lymph node metastasis, HER2, and Ki67 levels.•YAP protein is associated with favorable DFS and OS in luminal A breast cancer patients.•YAP protein is associated with favorable DFS in luminal B (HER2− or HER2+) breast cancer patients.•YAP protein is an independent predictor for DFS in IDC patients. |
| doi_str_mv | 10.1016/j.humpath.2017.08.032 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1938602838</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0046817717303210</els_id><sourcerecordid>1965439860</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-534e4bc02c8406f515df334472ed75152587fad38207d10eb498f4239c8fcd163</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EokvhJ4AscSmHBH_GzglV1fIhVaIScOjJ8toT6lU2WTxOVf59XXbhwKWnmZGemXn1voS85qzljHfvt-3Nstv7ctMKxk3LbMukeEJWXEvRWNmLp2TFmOoay405IS8Qt4xxrpV-Tk6EtX1vpFkRv77bZ0BM80TngV6vvzUecQ7JF4h0n-cCaaJn1-dX76ifIk0FaRjTlIIfKaafUxpqOwWgFdtk8FjonznTkhAXwJfk2eBHhFfHekp-fFx_v_jcXH799OXi_LIJSvel0VKB2gQmglWsGzTXcZBSKSMgmjoJbc3go7SCmcgZbFRvByVkH-wQIu_kKTk73K2if9W_xe0SBhhHP8G8oOO9tB0TVtqKvv0P3c5Lnqq6SnVayb6SldIHKuQZMcPg9jntfP7tOHMPGbitO2bgHjJwzLqaQd17c7y-bHYQ_239Nb0CHw4AVDtuE2SHIUH1LKYMobg4p0de3AMVLZlp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1965439860</pqid></control><display><type>article</type><title>Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Cao, Lanqing ; Sun, Ping-Li ; Yao, Min ; Jia, Meng ; Gao, Hongwen</creator><creatorcontrib>Cao, Lanqing ; Sun, Ping-Li ; Yao, Min ; Jia, Meng ; Gao, Hongwen</creatorcontrib><description>The transcriptional co-activator YES-associated protein (YAP) has been reported to act as both an oncogene and tumor suppressor in breast cancers. In this study, we evaluated YAP expression immunohistochemically in 324 breast cancer tissues and correlated the expression with clinicopathological findings and patient survival data. Additionally, we reviewed the literature to clarify the role of YAP in breast cancer. We detected YAP, estrogen receptor, progesterone receptor (PR), and human epidermal growth receptor-2 (HER2) expression and a Ki67 labeling index >20% in 53.4%, 49.0%, 45.0%, 28.3%, and 57.4% of invasive ductal carcinoma tissues, respectively. YAP is mainly localized within the tumor cell nuclei, and its expression was associated with the PR status and luminal A subtype. YAP expression also inversely correlated with the HER2 and Ki67 levels and lymph node metastasis. Kaplan-Meier curves revealed associations of YAP expression with favorable disease-free survival (DFS) and overall survival in patients with luminal A breast cancer and with favorable DFS association among patients with invasive ductal carcinoma, luminal B (HER2−), and luminal B (HER2+) breast cancers. A multivariate Cox analysis revealed that YAP expression and PR status were independent favorable predictors of DFS and overall survival, respectively, among patients with breast cancer, whereas tumor-node-metastasis stage and an old age were independent predictors of a poor DFS. Our results, together with the literature review findings, suggest that YAP could be a prognostic marker in patients with breast cancer.
•YAP protein is directly associated with PR status and luminal A subtype.•YAP protein is inversely associated with lymph node metastasis, HER2, and Ki67 levels.•YAP protein is associated with favorable DFS and OS in luminal A breast cancer patients.•YAP protein is associated with favorable DFS in luminal B (HER2− or HER2+) breast cancer patients.•YAP protein is an independent predictor for DFS in IDC patients.</description><identifier>ISSN: 0046-8177</identifier><identifier>EISSN: 1532-8392</identifier><identifier>DOI: 10.1016/j.humpath.2017.08.032</identifier><identifier>PMID: 28899737</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adaptor Proteins, Signal Transducing - analysis ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Apoptosis ; Biomarkers, Tumor - analysis ; Biopsy ; Breast cancer ; Breast Neoplasms - chemistry ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Cancer therapies ; Carcinoma - chemistry ; Carcinoma - mortality ; Carcinoma - secondary ; Carcinoma - therapy ; Cell growth ; Clinical significance ; Disease-Free Survival ; Drinking water ; Female ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Ki-67 Antigen - analysis ; Kinases ; Localization ; Lymphatic Metastasis ; Medical prognosis ; Medical records ; Metastasis ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Overall survival ; Phosphoproteins - analysis ; Proportional Hazards Models ; Proteins ; Receptor, ErbB-2 - analysis ; Receptors, Progesterone - analysis ; Retrospective Studies ; Risk Factors ; Time Factors ; Transcription Factors ; Yap</subject><ispartof>Human pathology, 2017-10, Vol.68, p.166-174</ispartof><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Oct 1, 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-534e4bc02c8406f515df334472ed75152587fad38207d10eb498f4239c8fcd163</citedby><cites>FETCH-LOGICAL-c459t-534e4bc02c8406f515df334472ed75152587fad38207d10eb498f4239c8fcd163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0046817717303210$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28899737$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cao, Lanqing</creatorcontrib><creatorcontrib>Sun, Ping-Li</creatorcontrib><creatorcontrib>Yao, Min</creatorcontrib><creatorcontrib>Jia, Meng</creatorcontrib><creatorcontrib>Gao, Hongwen</creatorcontrib><title>Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues</title><title>Human pathology</title><addtitle>Hum Pathol</addtitle><description>The transcriptional co-activator YES-associated protein (YAP) has been reported to act as both an oncogene and tumor suppressor in breast cancers. In this study, we evaluated YAP expression immunohistochemically in 324 breast cancer tissues and correlated the expression with clinicopathological findings and patient survival data. Additionally, we reviewed the literature to clarify the role of YAP in breast cancer. We detected YAP, estrogen receptor, progesterone receptor (PR), and human epidermal growth receptor-2 (HER2) expression and a Ki67 labeling index >20% in 53.4%, 49.0%, 45.0%, 28.3%, and 57.4% of invasive ductal carcinoma tissues, respectively. YAP is mainly localized within the tumor cell nuclei, and its expression was associated with the PR status and luminal A subtype. YAP expression also inversely correlated with the HER2 and Ki67 levels and lymph node metastasis. Kaplan-Meier curves revealed associations of YAP expression with favorable disease-free survival (DFS) and overall survival in patients with luminal A breast cancer and with favorable DFS association among patients with invasive ductal carcinoma, luminal B (HER2−), and luminal B (HER2+) breast cancers. A multivariate Cox analysis revealed that YAP expression and PR status were independent favorable predictors of DFS and overall survival, respectively, among patients with breast cancer, whereas tumor-node-metastasis stage and an old age were independent predictors of a poor DFS. Our results, together with the literature review findings, suggest that YAP could be a prognostic marker in patients with breast cancer.
•YAP protein is directly associated with PR status and luminal A subtype.•YAP protein is inversely associated with lymph node metastasis, HER2, and Ki67 levels.•YAP protein is associated with favorable DFS and OS in luminal A breast cancer patients.•YAP protein is associated with favorable DFS in luminal B (HER2− or HER2+) breast cancer patients.•YAP protein is an independent predictor for DFS in IDC patients.</description><subject>Adaptor Proteins, Signal Transducing - analysis</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Apoptosis</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biopsy</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - chemistry</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer therapies</subject><subject>Carcinoma - chemistry</subject><subject>Carcinoma - mortality</subject><subject>Carcinoma - secondary</subject><subject>Carcinoma - therapy</subject><subject>Cell growth</subject><subject>Clinical significance</subject><subject>Disease-Free Survival</subject><subject>Drinking water</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Kaplan-Meier Estimate</subject><subject>Ki-67 Antigen - analysis</subject><subject>Kinases</subject><subject>Localization</subject><subject>Lymphatic Metastasis</subject><subject>Medical prognosis</subject><subject>Medical records</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Staging</subject><subject>Overall survival</subject><subject>Phosphoproteins - analysis</subject><subject>Proportional Hazards Models</subject><subject>Proteins</subject><subject>Receptor, ErbB-2 - analysis</subject><subject>Receptors, Progesterone - analysis</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Time Factors</subject><subject>Transcription Factors</subject><subject>Yap</subject><issn>0046-8177</issn><issn>1532-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhi0EokvhJ4AscSmHBH_GzglV1fIhVaIScOjJ8toT6lU2WTxOVf59XXbhwKWnmZGemXn1voS85qzljHfvt-3Nstv7ctMKxk3LbMukeEJWXEvRWNmLp2TFmOoay405IS8Qt4xxrpV-Tk6EtX1vpFkRv77bZ0BM80TngV6vvzUecQ7JF4h0n-cCaaJn1-dX76ifIk0FaRjTlIIfKaafUxpqOwWgFdtk8FjonznTkhAXwJfk2eBHhFfHekp-fFx_v_jcXH799OXi_LIJSvel0VKB2gQmglWsGzTXcZBSKSMgmjoJbc3go7SCmcgZbFRvByVkH-wQIu_kKTk73K2if9W_xe0SBhhHP8G8oOO9tB0TVtqKvv0P3c5Lnqq6SnVayb6SldIHKuQZMcPg9jntfP7tOHMPGbitO2bgHjJwzLqaQd17c7y-bHYQ_239Nb0CHw4AVDtuE2SHIUH1LKYMobg4p0de3AMVLZlp</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>Cao, Lanqing</creator><creator>Sun, Ping-Li</creator><creator>Yao, Min</creator><creator>Jia, Meng</creator><creator>Gao, Hongwen</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201710</creationdate><title>Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues</title><author>Cao, Lanqing ; Sun, Ping-Li ; Yao, Min ; Jia, Meng ; Gao, Hongwen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-534e4bc02c8406f515df334472ed75152587fad38207d10eb498f4239c8fcd163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adaptor Proteins, Signal Transducing - analysis</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Apoptosis</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biopsy</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - chemistry</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer therapies</topic><topic>Carcinoma - chemistry</topic><topic>Carcinoma - mortality</topic><topic>Carcinoma - secondary</topic><topic>Carcinoma - therapy</topic><topic>Cell growth</topic><topic>Clinical significance</topic><topic>Disease-Free Survival</topic><topic>Drinking water</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Kaplan-Meier Estimate</topic><topic>Ki-67 Antigen - analysis</topic><topic>Kinases</topic><topic>Localization</topic><topic>Lymphatic Metastasis</topic><topic>Medical prognosis</topic><topic>Medical records</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Staging</topic><topic>Overall survival</topic><topic>Phosphoproteins - analysis</topic><topic>Proportional Hazards Models</topic><topic>Proteins</topic><topic>Receptor, ErbB-2 - analysis</topic><topic>Receptors, Progesterone - analysis</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Time Factors</topic><topic>Transcription Factors</topic><topic>Yap</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cao, Lanqing</creatorcontrib><creatorcontrib>Sun, Ping-Li</creatorcontrib><creatorcontrib>Yao, Min</creatorcontrib><creatorcontrib>Jia, Meng</creatorcontrib><creatorcontrib>Gao, Hongwen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Human pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cao, Lanqing</au><au>Sun, Ping-Li</au><au>Yao, Min</au><au>Jia, Meng</au><au>Gao, Hongwen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues</atitle><jtitle>Human pathology</jtitle><addtitle>Hum Pathol</addtitle><date>2017-10</date><risdate>2017</risdate><volume>68</volume><spage>166</spage><epage>174</epage><pages>166-174</pages><issn>0046-8177</issn><eissn>1532-8392</eissn><abstract>The transcriptional co-activator YES-associated protein (YAP) has been reported to act as both an oncogene and tumor suppressor in breast cancers. In this study, we evaluated YAP expression immunohistochemically in 324 breast cancer tissues and correlated the expression with clinicopathological findings and patient survival data. Additionally, we reviewed the literature to clarify the role of YAP in breast cancer. We detected YAP, estrogen receptor, progesterone receptor (PR), and human epidermal growth receptor-2 (HER2) expression and a Ki67 labeling index >20% in 53.4%, 49.0%, 45.0%, 28.3%, and 57.4% of invasive ductal carcinoma tissues, respectively. YAP is mainly localized within the tumor cell nuclei, and its expression was associated with the PR status and luminal A subtype. YAP expression also inversely correlated with the HER2 and Ki67 levels and lymph node metastasis. Kaplan-Meier curves revealed associations of YAP expression with favorable disease-free survival (DFS) and overall survival in patients with luminal A breast cancer and with favorable DFS association among patients with invasive ductal carcinoma, luminal B (HER2−), and luminal B (HER2+) breast cancers. A multivariate Cox analysis revealed that YAP expression and PR status were independent favorable predictors of DFS and overall survival, respectively, among patients with breast cancer, whereas tumor-node-metastasis stage and an old age were independent predictors of a poor DFS. Our results, together with the literature review findings, suggest that YAP could be a prognostic marker in patients with breast cancer.
•YAP protein is directly associated with PR status and luminal A subtype.•YAP protein is inversely associated with lymph node metastasis, HER2, and Ki67 levels.•YAP protein is associated with favorable DFS and OS in luminal A breast cancer patients.•YAP protein is associated with favorable DFS in luminal B (HER2− or HER2+) breast cancer patients.•YAP protein is an independent predictor for DFS in IDC patients.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28899737</pmid><doi>10.1016/j.humpath.2017.08.032</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0046-8177 |
| ispartof | Human pathology, 2017-10, Vol.68, p.166-174 |
| issn | 0046-8177 1532-8392 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1938602838 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adaptor Proteins, Signal Transducing - analysis Adult Age Factors Aged Aged, 80 and over Apoptosis Biomarkers, Tumor - analysis Biopsy Breast cancer Breast Neoplasms - chemistry Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - therapy Cancer therapies Carcinoma - chemistry Carcinoma - mortality Carcinoma - secondary Carcinoma - therapy Cell growth Clinical significance Disease-Free Survival Drinking water Female Humans Immunohistochemistry Kaplan-Meier Estimate Ki-67 Antigen - analysis Kinases Localization Lymphatic Metastasis Medical prognosis Medical records Metastasis Middle Aged Multivariate Analysis Neoplasm Staging Overall survival Phosphoproteins - analysis Proportional Hazards Models Proteins Receptor, ErbB-2 - analysis Receptors, Progesterone - analysis Retrospective Studies Risk Factors Time Factors Transcription Factors Yap |
| title | Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T20%3A09%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20YES-associated%20protein%20(YAP)%20and%20its%20clinical%20significance%20in%20breast%20cancer%20tissues&rft.jtitle=Human%20pathology&rft.au=Cao,%20Lanqing&rft.date=2017-10&rft.volume=68&rft.spage=166&rft.epage=174&rft.pages=166-174&rft.issn=0046-8177&rft.eissn=1532-8392&rft_id=info:doi/10.1016/j.humpath.2017.08.032&rft_dat=%3Cproquest_cross%3E1965439860%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1965439860&rft_id=info:pmid/28899737&rft_els_id=S0046817717303210&rfr_iscdi=true |